March 4 (Reuters) - Contineum Therapeutics Inc CTNM.O:
CONTINEUM THERAPEUTICS INITIATES PATIENT DOSING IN PHASE 1B CHRONIC PAIN TRIAL OF PIPE-791
CONTINEUM THERAPEUTICS INC - TOPLINE DATA FROM PIPE-791 PHASE 1B TRIAL EXPECTED IN EARLY 2026
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.